{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T22:15:09Z","timestamp":1786227309305,"version":"build-2736575974"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,4,14]],"date-time":"2010-04-14T00:00:00Z","timestamp":1271203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two recent randomized, controlled trials failed to demonstrate a benefit of mycophenolate mofetil (MMF) over prednisone in the treatment of myasthenia gravis (MG). We reviewed our experience with MMF in MG to determine whether these trials may have been unsuccessful because of their short duration and the unpredicted benefit of prednisone. We reviewed outcomes and prednisone dosage for all our acetylcholine\u2010receptor (AChR)\u2010antibody positive MG patients treated with MMF alone or with prednisone for at least 3 months. The percentage of patients with a desirable outcome (MG\u2010specific Manual Muscle Test score &lt;4 or Myasthenia Gravis Foundation of America post\u2010invention status of minimal manifestations or better) began to increase after 6 months; 80% of those followed for &gt;24 months had a desirable outcome. Prednisone dose decreased after 12 months; after 25 months, 54.5% of patients took no prednisone and 75% took &lt;7.5 mg\/day. This retrospective analysis provides class IV evidence that MMF begins to improve AChR\u2010positive MG after 6 months, both with prednisone and as monotherapy. Muscle Nerve 41: 593\u2013598, 2010<\/jats:p>","DOI":"10.1002\/mus.21640","type":"journal-article","created":{"date-parts":[[2010,4,14]],"date-time":"2010-04-14T23:12:10Z","timestamp":1271286730000},"page":"593-598","source":"Crossref","is-referenced-by-count":110,"title":["Mycophenolate mofetil in AChR\u2010antibody\u2010positive myasthenia gravis: Outcomes in 102 patients"],"prefix":"10.1002","volume":"41","author":[{"given":"Michael K.","family":"Hehir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Alpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Conaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald B.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,14]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1399-0012.1996.tb00651.x","article-title":"Purine metabolism and immunosuppressive effects of mycophenolate mofetil","volume":"10","author":"Allison AC","year":"1996","journal-title":"Clin Transplant"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20543"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.3.912-a"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.1.94"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.1.97"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120330501400110"},{"issue":"3","key":"e_1_2_5_8_2","first-page":"A137","article-title":"Mycophenolate mofetil (MyM) is safe and well\u2010tolerated in myasthenia gravis (MG)","volume":"54","author":"Cos L","year":"2000","journal-title":"Neurology"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.064"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000094122.88929.0B"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312373.67493.7f"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312374.95186.cc"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.031"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.14.2545"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.057"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6.1778"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb22937.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51317.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1981.tb33764.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410150316"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315656"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(91)90260-E"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000308705.27951.c2"},{"key":"e_1_2_5_25_2","first-page":"382","article-title":"MuSK\u2010antibody MG: response to various treatments in 32 patients","volume":"1132","author":"Sanders DB","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20069"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000327669.75695.38"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.21640","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.21640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:48:26Z","timestamp":1740012506000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.21640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,14]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1002\/mus.21640"],"URL":"https:\/\/doi.org\/10.1002\/mus.21640","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,14]]}}}